Understanding the mechanisms by which IL-10 and myeloid cells contribute to T-cell deficiency in GBM can provide valuable insights for developing targeted immunotherapies that aim to overcome these barriers and enhance the efficacy of immune-based treatments for GBM (Ravi et al., 2022). The gene discussed is IL10; the disease is glioblastoma.